Isis' partners are developing antisense drugs
invented by Isis to treat a wide variety of diseases.
The patent claims broadly cover antisense drugs
with "chimeric" or "gapmer" structures, including Isis' proprietary second-generation structures and the compositions of numerous other antisense compounds.
Isis and Lilly will continue to advance antisense drugs
identified during the previous collaboration, and continue their efforts to develop and refine antisense technologies.
Second-generation antisense drugs
offer greater potency, enhanced tolerability, and improved dosing convenience compared to first-generation antisense drugs
Inhalation could be used as the entrance of antisense drugs
into the body.
The promise of antisense drugs
lies in the theory that they work on a specific target disease without causing significant side effects.
announced today a cross-license agreement for the development of antisense drugs
targeting p53, a well-studied human protein that controls cellular response to genetic damage.
are short, chemically-modified RNA-like and DNA-like molecules that scientists design to complement a small, specific segment of messenger RNA.
a San Diego-based biotechnology company, to develop so-called antisense drugs
to block the activity of bcl-2.
AVI also has three ongoing Cooperative Research and Development Agreements (CRADAs) with various government agencies underway to test its antisense drugs
against a variety of infectious viruses:
We are optimistic that through the combination of Amgen's experience in discovering novel biopharmaceutical products and Isis' expertise in antisense technology, the prospects of new antisense drugs
reaching the market in the coming years has been greatly enhanced.
The potential market for antisense drugs
is huge, they gush -- about $25 billion by 1992, according to some company estimates.